National Institute of Dental & Craniofacial Research; Notice of Closed Meeting, 6891 [2021-01486]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
false accuracy claims and engage in
unfair, discriminatory conduct.6
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2021–01430 Filed 1–22–21; 8:45 am]
National Institutes of Health
BILLING CODE 6750–01–P
Government-Owned Inventions;
Availability for Licensing
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
National Institutes of Health,
HHS.
National Institutes of Health
ACTION:
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Carol A. Salata at 240–627–3727;
csalata@niaid.nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: NIDCR Special Grants
Review Committee.
Date: February 18–19, 2021.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Dental and
Craniofacial Research, National Institutes of
Health, 6701 Democracy Boulevard, Room
666, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Latarsha J. Carithers,
Scientific Review Officer, Scientific Review
Branch, National Institute of Dental and
Craniofacial Research, National Institutes of
Health, 6701 Democracy Boulevard, Room
666, Bethesda, MD 20892, 301–594–4859,
latarsha.carithers@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: January 19, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–01486 Filed 1–22–21; 8:45 am]
jbell on DSKJLSW7X2PROD with NOTICES
BILLING CODE 4140–01–P
6 Prepared Remarks of Commissioner Rohit
Chopra at Asia Pacific Privacy Authorities 54th
APPA Forum (Dec. 7, 2020), https://www.ftc.gov/
public-statements/2020/12/prepared-remarkscommissioner-rohit-chopra-asia-pacific-privacy.
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
Notice.
Prefusion-Stabilized Fusion (F)
Glycoprotein Vaccine Immunogens for
Human Metapneumovirus
Description of Technology:
Human metapneumovirus (hMPV)
infections have been shown as a
common cause of upper and lower
respiratory diseases such as
bronchiolitis and pneumonia in young
children, the elderly, and other
immunocompromised individuals.
Studies show that infections by the nonsegmented negative strand RNA virus
begin with attachment and entry of viral
glycoproteins that mediate fusion with
host cellular membranes. Like for the
human respiratory syncytial virus
(hRSV), a viral entry is initiated by the
fusion (F) protein. Given its role in
hMPV entry, the F protein has thus been
a target for eliciting neutralizing
antibodies and development of novel
protein-based therapeutic vaccines.
Researchers at the Vaccine Research
Center (VRC) of the National Institute of
Allergy and Infectious Diseases (NIAID)
developed improved recombinant
human metapneumovirus (hMPV) F
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
6891
proteins stabilized in the prefusion
conformation that can elicit potent
neutralizing antibodies against
infection. Double and triple stabilized
candidates were designed with interand intraprotomer disulfide mutations
that increase protein production and
show improved antigenic recognition by
prefusion-specific antibodies. These
second-generation immunogens
constitute an improvement over the first
generation constructs and are
characterized by additional stabilization
that results in optimal neutralization
responses.
The second-generation stabilized
prefusion hMPV F immunogens may be
an ideal vaccine immunogen to elicit
broad potent neutralizing antibodies
against metapneumovirus infection,
particularly in children and
immunocompromised adults.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications:
• A promising vaccine immunogen to
elicit broad potent neutralizing
antibodies against metapneumovirus
infection, particularly in children and
immunocompromised adults.
Competitive Advantages:
• There are no approved vaccines or
therapeutics against the second leading
cause of pediatric viral lower respiratory
tract infection in infants and young
children.
• Second-generation hMPV F
immunogens induce higher titer
neutralizing responses than firstgeneration versions in mice.
Development Stage: Preclinical
Research.
Inventors: Peter D. Kwong (NIAID);
Guillaume Stewart-Jones (NIAID); John
R. Mascola (NIAID); Ursula J. Buchholz
(NIAID); Peter L. Collins (NIAID); Jason
Gorman (NIAID); Li Ou,(NIAID);
Tongquing Zhou (NIAID); Baoshan
Zhang (NIAID); Wing-Pui Kong (NIAID);
Yaroslav Tsybovsky (NCI).
Publications: Liu, P., et al (2013). A
live attenuated human
metapneumovirus vaccine strain
provides complete protection against
homologous viral infection and crossprotection against heterologous viral
infection in BALB/c mice. Clinical and
Vaccine Immunology, 20(8), 1246–1254.
Battles, M.B., et al, (2017). Structure
and immunogenicity of pre-fusionstabilized human metapneumovirus F
glycoprotein. Nature communications,
8(1), 1–11.
Intellectual Property: HHS Reference
Number E–131–2019 includes U.S.
Provisional Patent Application Number
63/017,581, filed on 04/29/2020.
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 86, Number 14 (Monday, January 25, 2021)]
[Notices]
[Page 6891]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01486]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Dental & Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: NIDCR Special Grants Review Committee.
Date: February 18-19, 2021.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Dental and Craniofacial Research,
National Institutes of Health, 6701 Democracy Boulevard, Room 666,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Latarsha J. Carithers, Scientific Review
Officer, Scientific Review Branch, National Institute of Dental and
Craniofacial Research, National Institutes of Health, 6701 Democracy
Boulevard, Room 666, Bethesda, MD 20892, 301-594-4859,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral
Diseases and Disorders Research, National Institutes of Health, HHS)
Dated: January 19, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-01486 Filed 1-22-21; 8:45 am]
BILLING CODE 4140-01-P
